Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

被引：25
作者：
Perik, Patrick J. [1 ]
de Korte, Maarten Alexander [1 ]
van Veldhuisen, Dirk J. [1 ]
Gietema, Jourik A. [1 ]
Sleijfer, Dirk T. [1 ]
de Vries, Elisabeth G. E. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol & Cardiol, NL-9700 RB Groningen, Netherlands
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 12期
关键词：
breast cancer; cardiotoxicity; HER2; trastuzumab;
D O I：
10.1586/14737140.7.12.1763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.
引用
收藏
页码：1763 / 1771
页数：9
相关论文
共 63 条
[1]   Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy [J].
Baselga, J .
EUROPEAN JOURNAL OF CANCER, 1999, 35 :S324-S324
[2]  
Behr TM, 2001, NEW ENGL J MED, V345, P995
[3]   Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy [J].
Cardinale, D ;
Sandri, MT ;
Colombo, A ;
Colombo, N ;
Boeri, M ;
Lamantia, G ;
Civelli, M ;
Peccatori, F ;
Martinelli, G ;
Fiorentini, C ;
Cipolla, CM .
CIRCULATION, 2004, 109 (22) :2749-2754
[4]   Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J].
Cardinale, Daniela ;
Colombo, Alessandro ;
Sandri, Maria T. ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Civelli, Maurizio ;
Martinelli, Giovanni ;
Veglia, Fabrizio ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
CIRCULATION, 2006, 114 (23) :2474-2481
[5]   Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial [J].
Chia, Stephen ;
Clemons, Mark ;
Martin, Lee-Ann ;
Rodgers, Angela ;
Gelmon, Karen ;
Pond, Gregory R. ;
Panasci, Lawrence .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2773-2778
[6]   Docus on research: Herceptin and the heart - A molecular modifier of cardiac failure [J].
Chien, KR .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :789-790
[7]   ErbB2 is essential in the prevention of dilated cardiomyopathy [J].
Crone, SA ;
Zhao, YY ;
Fan, L ;
Gu, YS ;
Minamisawa, S ;
Liu, Y ;
Peterson, KL ;
Chen, J ;
Kahn, R ;
Condorelli, G ;
Ross, J ;
Chien, KR ;
Lee, KF .
NATURE MEDICINE, 2002, 8 (05) :459-465
[8]   111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure:: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity [J].
de Korte, M. A. ;
de Vries, E. G. E. ;
Lub-de Hooge, M. N. ;
Jager, P. L. ;
Gietema, J. A. ;
van der Graaf, W. T. A. ;
Sluiter, W. J. ;
van Veldhuisen, D. J. ;
Suter, T. M. ;
Sleiffer, D. T. ;
Perik, P. J. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) :2046-2051
[9]   MYOCYTE CELL-DAMAGE AFTER ADMINISTRATION OF DOXORUBICIN OR MITOXANTRONE IN BREAST-CANCER PATIENTS ASSESSED BY IN-111 ANTIMYOSIN MONOCLONAL-ANTIBODY STUDIES [J].
ESTORCH, M ;
CARRIO, I ;
MARTINEZDUNCKER, D ;
BERNA, L ;
TORRES, G ;
ALONSO, C ;
OJEDA, B .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1264-1268
[10]   The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight [J].
Ewer, Michael S. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) :2024-2025
1234567